How to use the speech recognition tool?
An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral,
Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1).
Status of the trial: Active, Not recruiting
Orphan Drug Recognition: Yes
- Opening Date: 2018-02-01
- Closing Date: 2019-02-01
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
- Retinal Rare Eye Diseases (WG1)
This ERN is supported by: